PRESS RELEASES

14 June 2021

CEBINA announces the launch of Danube Labs, a partnership with Evotec to develop cutting edge biotechnology projects sourced from Central and Eastern European Universities and Research Institutions
Read more

19 November 2020

Eveliqure announces the publication of key preclinical data for its clinical stage vaccine candidate against Shigellosis and ETEC

Read more

9 September 2020

Eveliqure announces the award of a NIAID contract to finance Phase 2 clinical
studies of its combined Shigella and ETEC vaccine candidate

Read more

4 May 2021

CEBINA reports potency of azelastine against emerging dominant variants of SARS-CoV-2 in laboratory testing
Read more



 

24 September 2020

Eveliqure announces the initiation of a Phase 1 clinical study of its combined Shigella and ETEC vaccine candidate

Read more

9 July 2020

CEBINA identifies a common antihistamine nasal spray as a potential anti-COVID-19 approach

Read more

17 February 2021

URSAPHARM Arzneimittel
and CEBINA announce partnership to repurpose the antihistamine azelastine to combat COVID-19

Read more


 

17 September 2020

CEBINA reports positive findings on the potency of azelastine, a widely used anti-histamine, as anti-COVID-19 approach

Read more

30 June 2020

Eveliqure secures further private investment to support development of its combined Shigella and ETEC vaccine candidate

Read more